Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.64) by 16.82 percent. This is a 36.36 percent decrease over losses of $(0.55) per share from the same period last year. The company reported quarterly sales of $48.50 million which beat the analyst consensus estimate of $43.72 million by 10.95 percent. This is a 66.80 percent increase over sales of $29.08 million the same period last year.